ArticleLeukemia2015
A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.
Abstract readLetter
In one paragraph
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 90 citations in OpenAlex.
- Trial
- Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.Annals of hematology · 2020Trial
- Clinical and molecular characteristics ofHaematologica · 2019Trial
- PD-1 Expression Promotes Immune Evasion in B-ALL.Hematology reports · 2025Article
- Transcriptomic profiling in canine B-cell lymphoma supports a synergistic effect of BTK and PI3K inhibitors.Frontiers in veterinary science · 2025Article
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.Cell communication and signaling : CCS · 2024Article
- TargetedCell reports methods · 2023Article
- MD-ALL: an Integrative Platform for Molecular Diagnosis of B-cell Acute Lymphoblastic Leukemia.Research square · 2023Article
- Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL.Genes · 2023Article
- The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.Cancers · 2023Review
- Oncogenic lesions and molecular subtypes in adults with B-cell acute lymphoblastic leukemia.Cancer science · 2023Review
- RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).PLoS genetics · 2022Article
- The genomic landscape of pediatric acute lymphoblastic leukemia.Nature genetics · 2022Article
- Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.International journal of molecular sciences · 2022Review
- ZNF384 rearrangement in acute lymphocytic leukemia with renal involvement as the first manifestation is associated with a poor prognosis: a case report.Molecular cytogenetics · 2022Article
- Whole transcriptome sequencing reveals a TCF4-ZNF384 fusion in acute lymphoblastic leukemia.Frontiers in oncology · 2022Article
- ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism.Frontiers in immunology · 2022Article
- A novel class of ZNF384 aberrations in acute leukemia.Blood advances · 2021Article
- Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 11 institutions in 1 country.
Y GochoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
N KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
H IchikawaDivision of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
K NakabayashiDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
T OsumiDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
T IshibashiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
H UenoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
K TeradaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
K ObokiDepartment of Molecular Medical Research, Tokyo Metropolitan Institute of Medical Science Setagaya-ku, Tokyo, Japan.
H SakamotoDivision of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Y ShiodaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
M ImaiDepartment of Pediatrics, Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan.
Y NoguchiDepartment of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
Y ArakawaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Y KojimaDepartment of Pediatrics, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan.
D ToyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
K HataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
T YoshidaDivision of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
K MatsumotoDepartment of Allergy and Immunology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
M KatoDepartment of Pediatrics, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
T FukushimaDepartment of Pediatrics, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
K KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
A ManabeDepartment of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.
A OharaDepartment of Pediatrics, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan.
Tokyo Children’s Cancer Study Group
National Center For Child Health and Development · JPJapanese Red Cross Narita Hospital · JPSaitama Children's Medical Center · JPMusashino Red Cross Hospital · JPShowa University Fujigaoka Hospital · JPSt. Luke's International Hospital · JPThe University of Tokyo · JPToho University · JPToho University Omori Medical Center · JPTokyo Metropolitan Institute of Medical Science · JPUniversity of Tsukuba · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene FusionAdolescentChildE1A-Associated p300 ProteinFemaleHumansMalePrecursor B-Cell Lymphoblastic Leukemia-LymphomaTrans-ActivatorsE1A-Associated p300 ProteinEP300 protein, humanTrans-ActivatorsZNF384 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.